Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo pill for diabetes and hypertension enters early human testing

NCT ID NCT07590466

First seen May 16, 2026 · Last updated Jun 22, 2026 · Updated 5 times

Summary

This early-stage trial will test a new tablet that combines two common drugs—one for type 2 diabetes and one for high blood pressure—in healthy volunteers. The goal is to see if the single pill works the same in the body as taking the two drugs separately. Thirty-six healthy adults will receive each treatment once in a random order, with blood samples taken to compare drug levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Olmesartan medoxomil and Dapagliflozin (fixed-dose combination tablet)

What this could lead to

If successful, this could lead to a simpler, single-pill treatment for people with both type 2 diabetes and high blood pressure.

What could go wrong

This is a very early, small study in healthy people, not patients. It only checks if the combo pill is absorbed similarly, not if it works better or is safer long-term.

Conditions

The condition(s) this trial relates to.

hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.